Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS-Reference-Cited by-同舟云学术

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS

Published:2012-07-10 Issue:5 Volume:36 Page:437-448
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Cremonini F.,Nicandro J. P.¹,Atkinson V.¹,Shringarpure R.¹,Chuang E.¹,Lembo A.²

Affiliation:

1. Southern Nevada VA Healthcare System; Las Vegas; NV; USA

2. Division of Gastroenterology; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston; MA; USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2012.05208.x/fullpdf

Reference40 articles.

1. Systematic review: the economic impact of irritable bowel syndrome;Inadomi;Aliment Pharmacol Ther,2003

2. Costs of irritable bowel syndrome in the UK and US;Maxion-Bergemann;Pharmacoeconomics,2006

3. The impact of irritable bowel syndrome on health-related quality of life;Gralnek;Gastroenterology,2000

4. Irritable bowel syndrome and surgery: a multivariable analysis;Longstreth;Gastroenterology,2004

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review;Archiv der Pharmazie;2024-07-23

2. Development and Validation of a High-Performance Liquid Chromatography Method to Quantify Marker Compounds in Lysimachia vulgaris var. davurica and Its Effects in Diarrhea-Predominant Irritable Bowel Syndrome;Molecules;2024-03-27

3. Application of metabolomics in irritable bowel syndrome in recent 5 years;International Immunopharmacology;2023-11

4. Irritable bowel syndrome;Handbook of Gastrointestinal Motility and Disorders of Gut-Brain Interactions;2023

5. Emerging therapies in the management of Irritable Bowel Syndrome (IBS);Expert Opinion on Emerging Drugs;2022-01-02